Optiver Holding B.V. Purchases 4,120 Shares of Abivax SA Sponsored ADR $ABVX

Optiver Holding B.V. raised its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 985.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,538 shares of the company’s stock after buying an additional 4,120 shares during the quarter. Optiver Holding B.V.’s holdings in Abivax were worth $505,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ABVX. GHP Investment Advisors Inc. boosted its position in shares of Abivax by 155.6% during the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after acquiring an additional 140 shares during the last quarter. WPG Advisers LLC increased its position in Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after purchasing an additional 253 shares during the last quarter. Assetmark Inc. raised its stake in Abivax by 41.5% during the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock valued at $99,000 after purchasing an additional 260 shares in the last quarter. SmartHarvest Portfolios LLC lifted its position in Abivax by 11.6% during the first quarter. SmartHarvest Portfolios LLC now owns 2,696 shares of the company’s stock valued at $300,000 after purchasing an additional 280 shares during the last quarter. Finally, Personal CFO Solutions LLC lifted its position in Abivax by 10.5% during the first quarter. Personal CFO Solutions LLC now owns 3,027 shares of the company’s stock valued at $337,000 after purchasing an additional 288 shares during the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. BTIG Research boosted their target price on shares of Abivax from $150.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Oddo Bhf reiterated an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Wolfe Research set a $136.00 price objective on Abivax in a research note on Wednesday, June 3rd. Finally, Morgan Stanley restated an “overweight” rating and set a $180.00 price objective on shares of Abivax in a research report on Friday, July 24th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $156.50.

Abivax Stock Performance

Shares of NASDAQ ABVX opened at $124.92 on Friday. Abivax SA Sponsored ADR has a fifty-two week low of $67.09 and a fifty-two week high of $148.83. The company has a market cap of $10.90 billion, a price-to-earnings ratio of -23.98 and a beta of 0.87. The business’s 50 day moving average price is $118.54 and its 200-day moving average price is $118.41.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. Sell-side analysts predict that Abivax SA Sponsored ADR will post -3.22 earnings per share for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.